Therapeutic Strategies Targeting PIK3CA Mutations in Bladder Cancer
Keywords:
Bladder cancer, PIK3CA gene mutations, Immunotherapy, Immune microenvironment, BioinformaticsAbstract
Background: Bladder cancer (BLCA) remains a significant global health burden with diverse incidence rates and mortality patterns. The advent of immunotherapy, particularly immune checkpoint inhibitors (ICIs), has transformed BLCA treatment paradigms. However, challenges persist, including resistance and biomarker identification.The phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) gene, implicated in BLCA pathogenesis, warrants investigation for its role in immune modulation and therapeutic responses.
Methods: This study integrated multi-omics data from The Cancer Genome Atlas (TCGA) to dissect PIK3CA mutations' impact on BLCA.
Results: PIK3CA mutations were associated with higher overall and disease-free survival rates. Transcriptomic analyses revealed differential gene expression, enriching immune-related pathways. PIK3CA mutations correlated with altered immune cell infiltration and immune checkpoint gene expression, indicating potential immunotherapeutic implications. Moreover, drug susceptibility analyses identified compounds showing differential responses based on PIK3CA mutation status.
Conclusion: These findings underscore PIK3CA's clinical relevance and its potential as a therapeutic Strategies in BLCA, offering insights for precision medicine approaches to enhance patient outcomes.
